Global Immunoglobulin Market Growth and Analysis by 2030

In terms of revenue, the global immunoglobulin market was valued at $13682.12 million in 2021 and is expected to reach $24859.40 million by 2030, growing at a CAGR of 6.87% during the forecast period of 2022 to 2030. The market study has also analyzed the impact of COVID-19 on the immunoglobulin market qualitatively as well as quantitatively.

GLOBAL IMMUNOGLOBULIN MARKET FORECAST 2022-2030

Global Immunoglobulin Market by Product (IGG, IGA, IGM, IGE, IGD) Market by Mode of Delivery (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Intramuscular Immunoglobulin) Market by Application (Hypogamma Globulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITB), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Other Applications) Market by Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Other Distribution Channels) Market by End-user (Hospitals & Clinics, Homecare) by Geography

Request free sample

Report Summary

To know more about this report, request a free sample copy

Immunoglobulins refer to antibodies produced naturally by the body’s immune system and help fight infections and diseases. These glycoprotein molecules are generated by plasma cells and act as a critical component of the body’s immune response. Immunoglobulins specifically recognize and bind to specific antigens like viruses and bacteria while aiding in their destruction.

Immunoglobulin-Markets

Read our latest blog on the Immunoglobulin Market

Key growth enablers for the global immunoglobulin market:

Growth in geriatric population
Prevalence of immunodeficiency diseases and autoimmune disorders
- Primary immune deficiency diseases refer to rare genetic disorders that impair the body’s immune system. Without a functional immune response, patients with diseases such as primary immune deficiency conditions may experience debilitating, chronic infections, like the Epstein-Barr virus, which can increase the risk associated with cancer development.
- Some primary immune deficiency diseases may also be fatal, depending upon the severity, and are diagnosed during infancy, childhood, as well as adulthood.
- According to an article published by the National Center for Biotechnology Information in 2020, more than 6 million people across the globe are affected by primary immunodeficiencies, and among these, 70% to 90% remain undiagnosed.
Increasing research and development activities

Key growth restraining factors:

High cost of therapy
High risk of side effects
- The majority of events like malaise, headache, flushing, fever, fatigue, chills, and lethargy are mild and transient. However, rare side effects such as thrombosis, arrhythmia, renal impairment, aseptic meningitis, transfusion-related acute lung injury (TRALI), and hemolytic anemia are critical. These are primarily associated with individual differences and specific immunoglobulin preparations.
- Performing an early assessment of risk factors, premedicating, infusing at a slow rate, as well as switching from intravenous immunoglobulin to subcutaneous immunoglobulin can help minimize these adverse effects.

Global Immunoglobulin Market | Top Trends

Increasing preferences for personalized medicines
- Immunoglobulin replacement therapy is essential for managing different primary immunodeficiency disease patients. Selecting a particular dose, product, and administration route requires understanding patient-specific risk factors and therapeutic immunoglobulin features. This would maximize tolerability and efficacy while also minimizing the risk factors.
- Moreover, individualizing therapy is also important to optimize patient outcomes as well as deliver precision benefits.
Increasing adoption of intravenous immunoglobulin (IVIG) treatments
- Intravenous immunoglobulin treatments and therapies are increasingly gaining popularity among patients. This is mainly because it is highly beneficial in diseases specific to organs, especially the disorders of the nervous system and skin.
- Also, it shows a higher efficacy in systemic autoimmune diseases, which includes Systemic Lupus Erythematosus (SLE).
Wide range of applications of immunoglobulin
- Immunoglobulins are used in the treatment of autoimmune diseases such as primary humoral immunodeficiency, multiple sclerosis, immune thrombocytopenia purpura, and autoimmune hemolytic anemia. Also, immunoglobulins have applications in various fields such as neurology, immunology, hematology, ophthalmology, nephrology, dermatology, rheumatology, and others.

Market Segmentation – Product, Mode of Delivery, Application, Distribution Channel, and End-User –

Market by Product:

IgG
- Under the product category, the IgG segment accounted for the largest market share in 2021 and is anticipated to dominate the market during the forecast period.
- There have been significant developments by market players across the globe in immunoglobulin G. For instance, in 2021, Beckman Coulter launched Access SARS-CoV-2 IgG, a completely quantitative lab-based serology test (immunoglobulin G) to measure antibodies’ quantity against the virus that causes COVID-19.
- Also, in 2020, Abbott received the CE Mark for a new quantitative lab-based serology test, known as SARS-CoV-2 IgG.
IgA
IgM
IgE
IgD

Market by Mode of Delivery:

Intravenous Immunoglobulin
- Intravenous immunoglobulin is expected to be the dominating mode of delivery over the forecasting years.
- Intravenous immunoglobulin is used to reduce the effects of inflammatory conditions involving the immune system, also known as autoimmune diseases. The United States Food and Drug Administration (FDA) is granting approvals to products and treatments involving intravenous immunoglobulin, as well. For instance, the approval for the supplemental Biologics License Application for PANZYGA®, an Immune Globulin Intravenous [Human] – ifas 10% Liquid Preparation of Pfizer Inc in 2021, and others.
Subcutaneous Immunoglobulin
Intramuscular Immunoglobulin

Market by Applications:

Hypogamma Globulinemia
Chronic Inflammatory Demyelinating Polyneuropathy
Inflammatory Myopathies
Specific Antibody Deficiency
Primary Immunodeficiency Diseases
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Other Applications

Market by Distribution Channel:

Hospital Pharmacy
Specialty Pharmacy
Other Distribution Channels

Market by End-User:

Hospitals & Clinics
Homecare

Geographical Study Based on Four Major Regions:

North America: The United States and Canada
- North America is anticipated to be the leading regional market with a share of 45.51% in 2021.
- It also accounts for the most lucrative region for major end-users in the market, such as hospitals & clinics and homecare.
- The high prevalence of different types of diseases, product approvals by the United States Food and Drug Administration (FDA) and the presence of prominent key companies operating in the region are some of the major factors expected to contribute to the growth of the market.
- As per the data published by the National Institutes of Health, around 500,000 people in the United States are suffering from over 200 different types of primary immunodeficiency disorders.
- In addition, industry leaders operating in the North America immunoglobulin market, such as CSL Behring, Pfizer Inc, ADMA Biologics, and others, create a wider scope for innovations through technological advancements as well as product developments.
Europe: The United Kingdom, Germany, France, Italy, Spain, Nordic countries, and Rest of Europe
Asia-Pacific: Japan, India, China, South Korea, Indonesia, Thailand, Vietnam, Australia, and Rest of Asia-Pacific
Rest of World: Latin America, Middle East & Africa

Major players operating in the global immunoglobulin market:

Biotest AG
China Biologic Products Inc
Grifols SA
LFB Group
CSL Behring

Key strategies adopted by some of these companies:

In 2021, Grifols acquired seven plasma centers from Kedrion with the intent to obtain about 240,000 liters of plasma per year. The $55 million will be financed with the company’s own resources.

In 2021, Pfizer received the US FDA clearance for the supplemental Biologics License Application with PANZYGA, an intravenous immunoglobulin for treating adult patients with chronic inflammatory demyelinating polyneuropathy.

Report Synopsis:

Report Scope	Details
Market Forecast Years	2022-2030
Base Year	2021
Market Historical Years	2018-2021
Forecast Units	Revenue ($ Million)
Segments Analyzed	Product, Mode of Delivery, Application, Distribution Channel, End-User
Geographies Analyzed	North America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed	Biotest AG, China Biologic Products Inc, Grifols SA, LFB Group, CSL Behring, Kedrion, Octapharma AG, Takeda Pharmaceutical Company Limited, Bio Products Laboratory, Shanghai RAAS Blood Products Co Ltd, Pfizer Inc, Sanquin Plasma Products BV, ADMA Biologics, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Kamada Ltd

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
MARKET DYNAMICS
- KEY DRIVERS
  - GROWTH IN GERIATRIC POPULATION
  - PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
  - INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
- KEY RESTRAINTS
  - HIGH COST OF THERAPY
  - HIGH RISK OF SIDE EFFECTS

KEY ANALYTICS
- IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
  - BUYERS POWER
  - SUPPLIERS POWER
  - SUBSTITUTION
  - NEW ENTRANTS
  - INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY BUYING CRITERIA
  - SOURCE
  - APPLICATION
  - EPITOPE
  - VALIDATION
- REGULATORY FRAMEWORK
MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED STATES
    - CANADA
- EUROPE
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED KINGDOM
    - GERMANY
    - FRANCE
    - SPAIN
    - ITALY
    - NORDIC COUNTRIES
    - REST OF EUROPE
- ASIA-PACIFIC
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - CHINA
    - JAPAN
    - INDIA
    - SOUTH KOREA
    - INDONESIA
    - THAILAND
    - VIETNAM
    - AUSTRALIA
    - REST OF ASIA-PACIFIC
- REST OF WORLD
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - REGIONAL ANALYSIS
    - LATIN AMERICA
    - MIDDLE EAST & AFRICA

COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
  - MERGERS & ACQUISITIONS
  - PRODUCT LAUNCHES & DEVELOPMENTS
  - PARTNERSHIPS & AGREEMENTS
  - BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
  - ADMA BIOLOGICS
  - BIO PRODUCTS LABORATORY
  - BIOTEST AG
  - CHINA BIOLOGIC PRODUCTS INC
  - CSL BEHRING
  - GRIFOLS SA
  - KAMADA LTD
  - KEDRION BIOPHARMA
  - LFB GROUP
  - OCTAPHARMA AG
  - PFIZER INC
  - SANQUIN PLASMA PRODUCTS BV
  - SHANGHAI RAAS BLOOD PRODUCTS CO LTD
  - SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
  - TAKEDA PHARMACEUTICAL COMPANY LIMITED

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – IMMUNOGLOBULIN

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 5: GLOBAL IGG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 6: GLOBAL IGG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 7: GLOBAL IGA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 8: GLOBAL IGA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 9: GLOBAL IGM MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 10: GLOBAL IGM MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 11: GLOBAL IGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 12: GLOBAL IGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 13: GLOBAL IGD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 14: GLOBAL IGD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 17: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 18: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 19: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 20: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 21: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 22: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 25: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 26: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 27: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 28: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 29: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 30: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 31: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 32: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 33: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 34: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 35: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 36: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 37: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 38: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 39: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 40: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 41: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 42: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 43: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 44: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 45: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 46: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 47: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 48: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 49: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 50: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 51: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 52: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 53: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 54: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 55: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 56: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 57: GLOBAL HOMECARE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 58: GLOBAL HOMECARE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 59: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 60: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 61: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 62: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 63: LEADING PLAYERS OPERATING IN NORTH AMERICA IMMUNOGLOBULIN MARKET

TABLE 64: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 65: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 66: LEADING PLAYERS OPERATING IN EUROPE IMMUNOGLOBULIN MARKET

TABLE 67: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 68: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 69: LEADING PLAYERS OPERATING IN ASIA-PACIFIC IMMUNOGLOBULIN MARKET

TABLE 70: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 71: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 72: LEADING PLAYERS OPERATING IN REST OF WORLD IMMUNOGLOBULIN MARKET

TABLE 73: LIST OF MERGERS & ACQUISITIONS

TABLE 74: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 75: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 76: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

FIGURE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)

FIGURE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)

FIGURE 9: GLOBAL IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)

FIGURE 10: GLOBAL IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)

FIGURE 11: GLOBAL IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)

FIGURE 12: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

FIGURE 13: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 14: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)

FIGURE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 20: GLOBAL IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)

FIGURE 21: GLOBAL IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 22: GLOBAL IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)

FIGURE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)

FIGURE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)

FIGURE 25: GLOBAL IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)

FIGURE 26: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 27: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

FIGURE 28: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 29: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 30: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)

FIGURE 31: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 32: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

FIGURE 33: GLOBAL IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)

FIGURE 34: NORTH AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 35: UNITED STATES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: CANADA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 38: UNITED KINGDOM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 39: GERMANY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: FRANCE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 41: SPAIN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: ITALY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: NORDIC COUNTRIES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 44: REST OF EUROPE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 45: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 46: CHINA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 47: JAPAN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 48: INDIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 49: SOUTH KOREA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 50: INDONESIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 51: THAILAND IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 52: VIETNAM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 53: AUSTRALIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 54: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 55: REST OF WORLD IMMUNOGLOBULIN MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)

FIGURE 56: LATIN AMERICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 57: MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

Segmentation

MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED STATES
    - CANADA
- EUROPE
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED KINGDOM
    - GERMANY
    - FRANCE
    - SPAIN
    - ITALY
    - NORDIC COUNTRIES
    - REST OF EUROPE
- ASIA-PACIFIC
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - CHINA
    - JAPAN
    - INDIA
    - SOUTH KOREA
    - INDONESIA
    - THAILAND
    - VIETNAM
    - AUSTRALIA
    - REST OF ASIA-PACIFIC
- REST OF WORLD
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - REGIONAL ANALYSIS
    - LATIN AMERICA
    - MIDDLE EAST & AFRICA